Infigratinib
21-162
Phase 1 small_molecule terminated
Quick answer
Infigratinib for Bladder Transitional Cell Carcinoma is a Phase 1 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Bladder Transitional Cell Carcinoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated